Suchergebnisse - "Domchek, Susan M"

PubPharm (18)

1

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer : A Phase II Multi-Cohort Study

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Drew, Y. | Kim, J. | Penson, R. | +25

2

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Brown, T. | Yablonovitch, A. | Till, J. | +11

CommentIn: Clin Cancer Res. 2023 Dec 15;29(24):5005-5007. - PMID 37787975

3

Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Wethington, S. | Shah, P. | Martin, L. | +16

4

Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer

enthalten in: Journal of the National Comprehensive Cancer Network : JNCCN | 2023

von Lau-Min, K. | McCarthy, A. | Nathanson, K. | +1

CommentIn: J Natl Compr Canc Netw. 2023 Apr;21(4):430-432. - PMID 37015334

5

Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer : final results from Study 10

enthalten in: British journal of cancer | 2023

von Kristeleit, R. | Drew, Y. | Oza, A. | +13

6

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors : Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial

enthalten in: JAMA oncology | 2023

von Schram, A. | Colombo, N. | Arrowsmith, E. | +20

CommentIn: JAMA Oncol. 2023 Jan 1;9(1):25-27. - PMID 36394835

7

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer : a randomised, phase 1b/2 trial

enthalten in: The Lancet. Oncology | 2022

von Reiss, K. | Mick, R. | Teitelbaum, U. | +10

CommentIn: Lancet Oncol. 2022 Aug;23(8):964-965. - PMID 35810753

8

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

enthalten in: The New England journal of medicine | 2021

von Tutt, A. | Garber, J. | Kaufman, B. | +137

CommentIn: Nat Rev Clin Oncol. 2021 Oct;18(10):607-608. - PMID 34282304

9

Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2019

von Kristeleit, R. | Oaknin, A. | Ray-Coquard, I. | +12

10

The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer

enthalten in: Clinical advances in hematology & oncology : H&O | 2018

von Domchek, S.